Cargando…

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy

OBJECTIVES: To explore clinically relevant differences in severity of vulvar and vaginal atrophy (VVA) in postmenopausal women treated with ospemifene compared with placebo. METHODS: Analysis of two multicenter, randomized, double-blind, 12-week phase-III studies in postmenopausal women (40–80 years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nappi, R. E., Panay, N., Bruyniks, N., Castelo-Branco, C., De Villiers, T. J., Simon, J. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438339/ https://www.ncbi.nlm.nih.gov/pubmed/25335119 http://dx.doi.org/10.3109/13697137.2014.975199

Ejemplares similares

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy
por: Bruyniks, N., et al.
Publicado: (2016)

Ospemifene for vulvar and vaginal atrophy: an overview
por: Palacios, Santiago
Publicado: (2020)

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
por: Palacios, Santiago, et al.
Publicado: (2016)

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014)

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
por: Blanco, Zuramis Estrada, et al.
Publicado: (2020)

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz, Gregory T, et al.
Publicado: (2014)

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
por: Soe, Lin H, et al.
Publicado: (2013)

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
por: López, Ana Rosa Jurado, et al.
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles
por: del Carmen Pingarrón Santofimia, María, et al.
Publicado: (2020)

Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use
por: Cagnacci, Angelo, et al.
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
por: Lilue, Mariella, et al.
Publicado: (2020)

Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey
por: Nappi, R. E., et al.
Publicado: (2016)

Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases
por: Goldstein, Andrew T., et al.
Publicado: (2016)

Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
por: Goldstein, Irwin, et al.
Publicado: (2019)

Effect of Ospemifene on Densitometric and Plasma Bone Metabolism Biomarkers in Postmenopausal Women Reporting Vulvar and Vaginal Atrophy (VVA)
por: Maffei, Silvia, et al.
Publicado: (2022)

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial
por: Constantine, G., et al.
Publicado: (2015)

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
por: Shin, Jae Jun, et al.
Publicado: (2017)

Current treatment options for postmenopausal vaginal atrophy
por: Naumova, Iuliia, et al.
Publicado: (2018)

Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
por: Edwards, D., et al.
Publicado: (2016)

Vaginal dehydroepiandrosterone compared to other methods of treating vaginal and vulvar atrophy associated with menopause
por: Pięta, Wojciech, et al.
Publicado: (2021)

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies
por: Salcedo, Félix Lugo, et al.
Publicado: (2020)

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study
por: Rodríguez, Silvia Pilar González
Publicado: (2020)

Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study
por: De Rosa, Nicoletta, et al.
Publicado: (2017)

Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis
por: Simon, James A., et al.
Publicado: (2023)

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program
por: Constantine, Ginger D., et al.
Publicado: (2015)

Human papillomavirus in vulvar and vaginal carcinoma cell lines.
por: Hietanen, S., et al.
Publicado: (1995)

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial
por: Archer, David F., et al.
Publicado: (2019)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

Multidisciplinary Overview of Vaginal Atrophy and Associated Genitourinary Symptoms in Postmenopausal Women
por: Goldstein, Irwin, et al.
Publicado: (2013)

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019)

Dermatographism with vulvar symptoms
por: Rivera, Sydney, et al.
Publicado: (2021)

Human papillomavirus in vulvar and vaginal carcinoma cell lines
Publicado: (1995)

Vulvar and Vaginal Melanomas—The Darker Shades of Gynecological Cancers
por: Dobrică, Elena-Codruța, et al.
Publicado: (2021)

Vulvar melanoma: relevant aspects in therapeutic management
por: Campaner, Adriana Bittencourt, et al.
Publicado: (2017)

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
por: Archer, David F., et al.
Publicado: (2015)

Vulvar and Vaginal Graft versus Host Disease: A Healthcare Clinic Initiative
por: Van Dam, Naomi, et al.
Publicado: (2017)

Clinical outcomes of distal vaginal and vulvar cancer treated with image-guided brachytherapy
por: Yaney, Alexander, et al.
Publicado: (2021)

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials
por: Simon, James A., et al.
Publicado: (2018)

Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study
por: Nordstrom, Beth L., et al.
Publicado: (2022)

Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
por: Duarte-Franco, Eliane, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_1jb1glbkt4bic24svhq01q9nku